Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis
In the context of the Omicron variant during the COVID-19 pandemic, the use of early oral antiviral agents in vaccinated individuals was found to be more expensive compared to avoid treatment, primarily due to the high costs associated with it. To enhance the efficiency in resource allocation, it is essential to pursue policies aimed at reducing drug costs, along with conducting further pharmaco-economic studies.
Authors
- Nicolò Presa
- Vincenzo Scaglione (ORCID: https://orcid.org/0000-0002-2911-2255)
- Umberto Restelli (ORCID: https://orcid.org/0000-0001-6831-3044)
- Samuele Gardin
- Anna Maria Cattelan (ORCID: https://orcid.org/0000-0003-2869-2945)
- Sofia Silvola (ORCID: https://orcid.org/0000-0002-9679-5164)
- Lolita Sasset
- Anna Rossetto (ORCID: https://orcid.org/0000-0002-2682-4898)
- Deris Gianni Boemo
Institutions
- University of Padua (IT)
- University Carlo Cattaneo (IT)
Publication Details
- Journal
- European journal of medical research
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s40001-024-02154-2
- Citations
- 2
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.78